AMENDMENT TO CREDIT AGREEMENTCredit Agreement • February 15th, 2023 • Biogen Inc. • Biological products, (no disgnostic substances) • New York
This CREDIT AGREEMENT (this “Agreement”) is entered into as of January 28, 2020, among BIOGEN INC., a Delaware corporation (the “Borrower”), each Lender from time to time party hereto, and BANK OF AMERICA, N.A., as Administrative Agent, Swing Line Lender and L/C Issuer.
NONQUALIFIED STOCK OPTION AWARD AGREEMENT GRANTED UNDER BIOGEN INC. 2017 OMNIBUS EQUITY PLANNonqualified Stock Option Award Agreement • February 15th, 2023 • Biogen Inc. • Biological products, (no disgnostic substances) • Delaware
AMENDED AND RESTATED COLLABORATION AGREEMENTCommercialization Agreement • February 15th, 2023 • Biogen Inc. • Biological products, (no disgnostic substances)
Exhibit 1(I) - Form of Quarterly Forecast and Quarterly Report Exhibit 2.2(a)(ii) - Minimum Shared Development Information Content Exhibit 3.1(a)(i) - E2609 Eisai Collaboration Product Development Plan
FIRST AMENDMENT TO AMENDED AND RESTATED COLLABORATION AGREEMENTCollaboration Agreement • February 15th, 2023 • Biogen Inc. • Biological products, (no disgnostic substances)
This First Amendment to the Amended and Restated Collaboration Agreement (this “Amendment”) is entered into as of March 13, 2022 (the “Amendment Effective Date”), by and between Eisai Co., Ltd., a Japanese corporation, with a place of business at 4-6-10, Koishikawa, Bunkyo-ku Tokyo 112-8088, Japan (“Eisai”) and Biogen MA Inc., a Massachusetts corporation, with a place of business at 225 Binney Street, Cambridge, MA 02142 (“Biogen”). Eisai and Biogen may each be referred to herein as a “Party”, and together as the “Parties”.
